A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination With Hydroxychloroquine (Autophagy Inhibitor) in Patients With Advanced Malignancies
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2017
At a glance
- Drugs Sirolimus (Primary) ; Vorinostat (Primary) ; Hydroxychloroquine
- Indications Cancer
- Focus Adverse reactions
- 12 Jul 2017 Planned primary completion date changed from 1 Apr 2018 to 1 Apr 2019.
- 12 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 25 Oct 2016 Planned number of patients changed from 236 to 224.